These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Trent JC; Patel SS; Zhang J; Araujo DM; Plana JC; Lenihan DJ; Fan D; Patel SR; Benjamin RS; Khakoo AY Cancer; 2010 Jan; 116(1):184-92. PubMed ID: 19885836 [TBL] [Abstract][Full Text] [Related]
3. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Perik PJ; Rikhof B; de Jong FA; Verweij J; Gietema JA; van der Graaf WT Ann Oncol; 2008 Feb; 19(2):359-61. PubMed ID: 17962203 [TBL] [Abstract][Full Text] [Related]
4. Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors. Yachoui R Am J Ther; 2014; 21(5):e148-50. PubMed ID: 23567788 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. Eisenberg BL; Harris J; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M J Surg Oncol; 2009 Jan; 99(1):42-7. PubMed ID: 18942073 [TBL] [Abstract][Full Text] [Related]
6. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339 [TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Pariente A; Etcharry F; Cales V; Laborde Y; Ferrari S; Biour M Eur J Gastroenterol Hepatol; 2006 Jul; 18(7):785-7. PubMed ID: 16772838 [TBL] [Abstract][Full Text] [Related]
8. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report. Samanci NS; Guliyev M; Degerli E; Celik E; Turna ZH J Cancer Res Ther; 2022; 18(3):792-794. PubMed ID: 35900559 [TBL] [Abstract][Full Text] [Related]
9. MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate. Warakaulle DR; Gleeson F AJR Am J Roentgenol; 2006 Feb; 186(2):510-5. PubMed ID: 16423961 [TBL] [Abstract][Full Text] [Related]
10. The safety profile of imatinib in CML and GIST: long-term considerations. Thanopoulou E; Judson I Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109 [TBL] [Abstract][Full Text] [Related]
11. New strategies for treating GIST when imatinib fails. Boyar MS; Taub RN Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208 [TBL] [Abstract][Full Text] [Related]
12. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients. Gelibter A; Milella M; Ceribelli A; Zeuli M; Ferraresi V; Vecchione A; Cognetti F Anticancer Res; 2004; 24(5B):3147-51. PubMed ID: 15510603 [TBL] [Abstract][Full Text] [Related]
13. Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy. Shankar S; Dundamadappa SK; Karam AR; Stay RM; van Sonnenberg E Acta Radiol; 2009 Oct; 50(8):837-44. PubMed ID: 19735005 [TBL] [Abstract][Full Text] [Related]
14. Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour. Pulido EG; Riquelme A; Ballesteros J; Vaz MÁ Anticancer Drugs; 2012 Jun; 23 Suppl():S15-7. PubMed ID: 22739666 [TBL] [Abstract][Full Text] [Related]
15. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Verweij J; Casali PG; Kotasek D; Le Cesne A; Reichard P; Judson IR; Issels R; van Oosterom AT; Van Glabbeke M; Blay JY Eur J Cancer; 2007 Apr; 43(6):974-8. PubMed ID: 17336514 [TBL] [Abstract][Full Text] [Related]
16. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. Kim H; Chang HM; Ryu MH; Kim TW; Sohn HJ; Kim SE; Kang HJ; Park S; Lee JS; Kang YK J Korean Med Sci; 2005 Jun; 20(3):512-5. PubMed ID: 15953881 [TBL] [Abstract][Full Text] [Related]
17. Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor. Enck RE; Abushahin F; Bossaer JB J Oncol Pharm Pract; 2014 Apr; 20(2):137-40. PubMed ID: 23676509 [TBL] [Abstract][Full Text] [Related]
18. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568 [TBL] [Abstract][Full Text] [Related]